A Corcept Director Holds 1.5 Million Shares Through a 50% Crash and Rebound

James N. Wilson, a director at Corcept Therapeutics Incorporated (CORT +1.16%), sold 10,000 shares of the company on July 15, 2026, according to an SEC Form 4 filing.

Transaction summary

Transaction value based on SEC Form 4 weighted average sale price ($88.30); post-transaction value based on July 15, 2026 market close ($89.57).

Key questions

• What was the structural mechanism behind this transaction?
  The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2026, which allows insiders to sell a predetermined number of shares at set times to avoid concerns about trading on non-public information.
• How is the insider’s remaining equity distributed?
  Wilson’s remaining position of about 1.5 million shares is held through three indirect entities: the James N. Wilson and Pamela D. Wilson Trust (1,084,543 shares), the James N. Wilson 2025 Grantor Retained Annuity Trust (200,000 shares), and the Pamela D. Wilson 2025 Grantor Retained Annuity Trust (200,000 shares).
• What is the recent performance context for the stock?
  At the time of the transaction on July 15, 2026, the company’s shares had achieved a one-year return of about 25%, providing a backdrop of price appreciation for this routine liquidity event.

Company Overview

Company Snapshot

• Corcept Therapeutics is a specialty pharmaceutical company that discovers, develops, and commercializes treatments for serious metabolic, oncological, and neuropsychiatric disorders, with its flagship product Korlym (mifepristone) tablets generating substantial revenue from adult patients with endogenous Cushing’s syndrome.
• The company operates a focused business model centered on the development and commercialization of targeted pharmaceutical therapies, generating revenue primarily through the sale of its approved medications to healthcare providers and patients in the United States.
• Corcept Therapeutics serves physicians and patients within specialty care settings, particularly those treating endocrine disorders and other serious metabolic conditions, with a target market encompassing hospital systems, specialty clinics, and individual practitioners across the United States.

Corcept Therapeutics is a specialty pharmaceutical company with a market capitalization of $9.6 billion, generating TTM revenues of $769.1 million and net income of $47.3 million. The company maintains a focused pipeline strategy centered on its commercial flagship Korlym, which addresses a significant unmet medical need in endogenous Cushing’s syndrome treatment, positioning it as a specialized player within the pharmaceutical sector with demonstrated profitability and revenue growth momentum.

What this transaction means for investors

Wilson sold at $88.30, which is roughly two and a half times where this stock closed on the last day of 2025, when the New Year’s Eve session wiped out 50% of Corcept’s value in a day, dropping shares to $34.83 after the FDA rejected relacorilant for hypercortisolism. That means the plan he adopted in March was written into a recovery, not a decline, and the timing looks less like a call than a schedule catching a rebound. His trusts still hold about 1.5 million shares, including two grantor retained annuity trusts set up last year, which is estate planning rather than exit planning.

Meanwhile, the ongoing rebound has a cause. The same drug the FDA turned away in December won approval in ovarian cancer, and Corcept raised full-year revenue guidance to between $950 million and $1.05 billion. CEO Joseph Belanoff said after the rejection he was “confident we will find a way” forward. For long-term investors, the December gap is an important lesson. One regulatory letter halved this company, and its next act still depends on how far a single molecule can stretch.